Summit Therapeutics Inc. (SMMT): Capital Expenditures
$657.0K
Year ended 2025-12-31
$1.39M
Trailing 12 months to 2026-06-30
+1.7%
3-year compound annual growth
+9.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $657.0K | +372.7% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $139.0K | +8.6% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $128.0K | -79.5% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $624.0K | +103.9% | 2025-02-24, From 2022-01-01 |
| 2021-12-31 | $306.0K | -27.3% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $421.0K | n/a | 2022-12-21, From 2020-01-01 |
| No annual figure between 2019-01-31 and 2020-12-31. | |||
| 2019-01-31 | $157.0K | n/a | 2021-03-31, From 2018-02-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $657.0K | +372.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $630.0K | -35.2% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $13.15M | -55.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Spyre Therapeutics, Inc. (SYRE) | 2024-12-31 | $0 | n/a |
Compare SMMT, KNSA, KURA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗